The Rise of Life Sciences Real Estate Clusters in Indian Pharma Hubs

India's pharmaceutical and life sciences industry — the world's third-largest by volume and thirteenth largest by value — is driving the emergence of a specialised real estate category that has generated enormous value for investors in the US, UK, and Europe. Life sciences real estate in India encompasses pharmaceutical manufacturing plants, R&D facilities, biotech incubators, clinical research organisations, and medical device manufacturing — a diverse ecosystem with distinct real estate requirements that generalist industrial developers are ill-equipped to serve.

Hyderabad's Genome Valley is India's most established life sciences real estate cluster, hosting over 200 companies across pharmaceutical manufacturing, biotech research, clinical trials, and medical devices. The cluster — spanning Turkapally, Shameerpet, and Shadnagar — benefits from deliberate Telangana government support, proximity to Hyderabad's international airport, and a deep talent pool from institutions like BITS Pilani Hyderabad, ISB, and the University of Hyderabad. Key real estate developers in Genome Valley include TSIIC (Telangana State Industrial Infrastructure Corporation), which provides serviced plots, and private developers who have built turn-key GMP-compliant manufacturing facilities.

Gujarat's pharmaceutical cluster — centred on the Vadodara-Ankleshwar industrial belt and the Ahmedabad-Changodar corridor — is India's largest pharma manufacturing hub, accounting for over 35% of India's pharmaceutical exports. The state's Pharma SEZ at Pharma City near Vadodara and the GIDC estates across South Gujarat provide the industrial real estate backbone for hundreds of domestic and multinational pharma companies.

For real estate investors, life sciences facilities offer premium yields (9–12% cap rates vs 7.5–8.5% for standard industrial) reflecting the specialised fit-out (cGMP-compliant clean rooms, specialised HVAC, dedicated effluent treatment), longer lease terms (10–20 years for large pharma operators), and the regulatory barriers to entry that make lease renewal almost certain for compliant facilities. The entry of Blackstone, Piramal Fund Management, and global life sciences REIT operators into India's pharma real estate market signals growing institutional conviction in the sector.